Business Wire

ITRS-GROUP

1.6.2022 10:02:12 CEST | Business Wire | Press release

Share
ITRS Group Launches Obcerv: Next Generation Technology Takes Performance Monitoring to the Next Level

ITRS Group, leading provider of real-time enterprise monitoring and analytics software to global financial institutions, today announces the launch of its newest product offering, Obcerv.

Amidst rapid digital transformation, modern IT operations have evolved from a traditional on-premises system to increasingly complex hybrid cloud environments. Traditional monitoring no longer addresses the complexities of the modern IT services stack and firms face a growing challenge to centralise data monitoring that can enhance performance, reveal patterns and trends in resource utilisation, and reduce outages.

The launch of Obcerv will introduce end-to-end visibility into infrastructure and applications, and through intelligent alert aggregation, it will identify the most likely source of a problem, enabling users to improve service delivery. Obcerv will act as both a data storage and analytics platform for critical monitoring, allowing users to gain full visibility and ultimately take back control of their systems.

Obcerv simplifies and accelerates traditionally complex monitoring systems with benefits including but not limited to:

  • The intelligent correlation of data from multiple data feeds and streams to simplify analysis
  • Data compression minimises storage costs, without having to aggregate the data as many tools do, ensuring data fidelity is maintained
  • Root cause analysis is accelerated, offering alerts based on commonality, thereby providing context and meaning to alerts
  • Unique APIs facilitate full interoperability, Obcerv can store data from other ITRS Group products, but from monitoring tools from other vendors too

Guy Warren, CEO of ITRS Group, said: “Monitoring is often seen as the canary in the coal mine: it may be able to tell you that something is wrong, but too often the message lacks context and meaning. Obcerv will provide IT operators with an understanding around why certain things happen, allowing them to accurately decide the best course of action.

In recent years, modern IT estates have become extremely complex, pushing many monitoring teams to the edge of their capability, leaving them struggling to deliver on uptime and reliability metrics. And with more than half of all firms experiencing at least a day of downtime each year, it is clear that monitoring solutions that are able to match the increasing complexities of the systems they are monitoring is required. Obcerv will not only help firms to gain full visibility across their estates but in doing so, it will enable them to regain control of them.”

For more information, visit www.itrsgroup.com/products/obcerv

About ITRS Group

ITRS Group ensures operational resilience for enterprises engaged in transforming their IT estate for a digital future, as well as the ongoing health of their on-premise, cloud-based or hybrid IT estate. By transforming the mass of raw data on performance, resource usage, and cost, ITRS Group’s solutions can detect and actively prevent problems and maximise cost efficiency, reassuring enterprises that their IT estates are running effectively. With experience in legacy technologies as well as the dynamic environment of cloud-delivery, agile development, and service-based architecture, ITRS Group’s people and software serve more than 4500 clients across industry markets. As new disruptors, new technologies, and new regulations continue to shape the marketplace and change the expectations of consumers, ITRS Group offers a best-in-class service and is a source of confidence for the always-on enterprise.

For more information, visit www.itrsgroup.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye